Transcranial Electrical Stimulation for Parkinson's Disease Motor Symptoms
Transcranial Electrical Stimulation Device
Synucleinopathies+17
+ Basal Ganglia Diseases
+ Brain Diseases
Treatment Study
Summary
Study start date: January 1, 2026
Actual date on which the first participant was enrolled.The study is focused on using a new technology called transcranial electrical stimulation (tES) to help manage movement symptoms in people with Parkinson's disease. This technology, delivered through a device known as Sphere V3.0, aims to non-invasively stimulate parts of the brain that control movement. It is significant as it offers a potential treatment without the need for surgery or medication, which may provide a safer alternative for managing symptoms. The study targets individuals with Parkinson's and uses a fully remote setup, allowing participants to receive and use the device at home. Participants are sent the Sphere V3.0 device through the mail, along with instructions and video tutorials. They are trained through video calls to correctly set up and use the device, which involves placing electrodes on the head to deliver the stimulation. The study measures the effectiveness of the treatment by analyzing participants' movements through video assessments. These videos are taken at specific times and angles to ensure consistency. Safety is a priority, with 24/7 emergency support, regular digital diary entries for reporting minor issues, and a structured response plan for more serious events. All data is securely collected and stored, ensuring participants' privacy throughout the study.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.30 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 80 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location